- In response to recent media commentary, the Board of Directors of Algeta ASA confirms that it is in receipt of a preliminary acquisition proposal from Bayer AG.
- The commentary in the media refers to an acquisition proposal at a price of NOK 306 per Algeta share. This is incorrect. The preliminary acquisition proposal is NOK 336 per Algeta share.
- There is no certainty that this preliminary acquisition proposal will lead to a transaction or as to the terms of any such transaction.
OSLO, Norway, Nov. 26, 2013 (GLOBE NEWSWIRE) -- The Board of Directors of Algeta ASA (OSE: ALGETA) today announced that it is in receipt of a preliminary acquisition proposal from Bayer AG which may or may not lead to a transaction. Discussions are at an early stage and further announcements may be made, as appropriate, in due course.
For further information, please contact:
|Oystein Soug||+47 90 65 65 25|
|Mike Booth||+1 646 410 1884|
|Communications & Corporate Affairsemail@example.com|
Algeta is a company focused on developing, manufacturing and marketing novel targeted therapies for patients with cancer. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com.
Press release: http://hugin.info/134655/R/1745705/587555.pdf